Workflow
Cell重磅:华人团队开发新型镇痛药物,效果突出且避免成瘾等副作用
生物世界·2025-05-20 03:03

Core Viewpoint - The article discusses the development of a new non-addictive pain relief drug, SBI-810, which targets neurotensin receptor-1 (NTSR1) and offers effective pain management without the severe side effects associated with opioid medications [3][10]. Group 1: Pain Management and Opioid Crisis - Pain is the primary reason for seeking medical care, affecting over 600 million people globally, with opioid medications widely used despite addiction risks [2]. - The economic burden and social impact of opioid use disorder have prompted U.S. healthcare agencies to prioritize the development of safer alternatives [2]. Group 2: Research and Development of SBI-810 - SBI-810 is a novel analgesic that provides strong pain relief for both acute and chronic pain, demonstrating more precise action than opioids by selectively activating the β-arrestin2 signaling pathway [3][8]. - The research team has applied for multiple patents related to SBI-810 and plans to initiate human clinical trials soon [3]. Group 3: Mechanism of Action - SBI-810's analgesic effects require NTSR1 and β-arrestin2 but do not involve NTSR2 or β-arrestin1, inhibiting excitatory synaptic transmission in spinal cord nociceptive neurons [8]. - It reduces the expression of Nav1.7 in primary sensory neurons and diminishes the response of C fibers, effectively blocking both peripheral and central sensitization [8][10]. Group 4: Benefits Over Opioids - SBI-810 alleviates common opioid-related side effects such as constipation and tolerance, and it reduces withdrawal symptoms associated with opioid use [8]. - The findings highlight the potential of NTSR1 biased allosteric modulators as a promising non-addictive pain management strategy, addressing both acute and chronic pain [10].